doi: 10.1089/apc.2007.9970.
FDA approves maraviroc tablets
- PMID: 17919097
- DOI: 10.1089/apc.2007.9970
Item in Clipboard
FDA approves maraviroc tablets
AIDS Patient Care STDS.
2007 Sep.
No abstract available
Similar articles
-
FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.AIDS Alert. 2007 Sep;22(9):103. AIDS Alert. 2007. PMID: 18411462 No abstract available.
-
An in-depth look at the challenges of prescribing maraviroc.HIV Clin. 2008 Summer;20(3):9-11. HIV Clin. 2008. PMID: 18814378 No abstract available.
-
FDA panel backs HIV drug.AIDS Read. 2007 Jun;17(6):294. AIDS Read. 2007. PMID: 17632933 No abstract available.
-
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.J Clin Pharm Ther. 2010 Dec;35(6):657-63. doi: 10.1111/j.1365-2710.2009.01148.x. J Clin Pharm Ther. 2010. PMID: 21054456 Review.
-
Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.Expert Opin Pharmacother. 2008 Dec;9(18):3231-42. doi: 10.1517/14656560802576324. Expert Opin Pharmacother. 2008. PMID: 19040343 Review.
Cited by
-
Naturally occurring Vpr inhibitors from medicinal plants of Myanmar.J Nat Med. 2017 Oct;71(4):579-589. doi: 10.1007/s11418-017-1104-7. Epub 2017 Jul 5. J Nat Med. 2017. PMID: 28681118 Free PMC article. Review.
-
Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc.HIV AIDS (Auckl). 2010;2:51-8. doi: 10.2147/hiv.s4977. Epub 2010 Mar 19. HIV AIDS (Auckl). 2010. PMID: 22096384 Free PMC article.
-
Prediction of Coreceptor Tropism in HIV-1 Subtype C in Botswana.Viruses. 2023 Jan 31;15(2):403. doi: 10.3390/v15020403. Viruses. 2023. PMID: 36851617 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
